Hexarelin 2mg

Hexarelin 2mg — Research Overview

Hexarelin is a synthetic hexapeptide from the growth hormone secretagogue (GHS) family. Its sequence — His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 — was specifically designed to trigger growth hormone release by interacting with the ghrelin receptor (GHS-R1a). It’s actually one of the more potent GH secretagogues studied in preclinical models. Unlike natural ghrelin, hexarelin doesn’t cause a major spike in appetite. This makes it a useful tool for researchers looking to separate GH-releasing effects from the orexigenic arms of ghrelin receptor signalling in laboratory settings.

Mechanism of Action

Hexarelin binds to GHS-R1a receptors found mostly in the hypothalamus and pituitary gland. Once it binds, it kicks off intracellular signalling cascades—mainly through phospholipase C and protein kinase C pathways—which lead to the pulsatile release of growth hormone from somatotroph cells. This process seems to be additive when researchers combine it with growth hormone releasing hormone (GHRH), suggesting these two pathways meet at different but complementary points. Investigators looking into pituitary function and GH pulsatility use hexarelin as a pharmacological probe to figure out how these upstream signals control downstream GH secretion.

Hexarelin also binds the CD36 scavenger receptor with a high affinity, which isn’t a trait shared by most other GH secretagogues. Since CD36 is found on macrophages, endothelial cells, and cardiomyocytes, it’s tied to lipid uptake, inflammation regulation, and cardiac function. Research into hexarelin’s cardioprotective properties suggests this CD36 interaction might explain effects that seem independent of GH secretion. For those studying cardiovascular biology, this dual-receptor profile is worth a closer look.

Research Context

When researchers give hexarelin to rodent models, they’ve seen significant spikes in circulating IGF-1. This downstream mediator of GH action is vital for tissue growth, repair, and metabolic regulation. Some teams studying animal body composition have noted lean mass changes that align with elevated GH signalling, and hexarelin’s also cropped up in studies looking at hepatic lipid metabolism.

Cardiovascular studies have looked into hexarelin’s effects using models of ischemic injury. Several research groups found that hexarelin treatment helped preserve cardiac function and reduced fibrosis in rodent models of myocardial ischemia, though the exact mechanisms are still being investigated. It isn’t yet clear if these effects are primarily GH-mediated, CD36-mediated, or a combination of both; the current literature hasn’t fully resolved the issue.

When researchers compare various GH secretagogues, they often use hexarelin alongside Ipamorelin 2mg and GHRP-6 5mg to map out how the GHS-R1a pathway behaves under different conditions. Hexarelin usually triggers stronger GH pulses in acute settings than ipamorelin, though the latter is known for its cleaner selectivity profile. These comparisons help us understand receptor dynamics and why downstream signalling varies so much. Scientists also combine hexarelin with CJC-1295 W/O DAC 2mg or Sermorelin 2mg in research models to look at synergistic GH release and how pulsatile secretion patterns are amplified. This material is for research purposes only and is not intended for human administration; it should be handled by qualified investigators only.

Laboratory Handling

Hexarelin comes as a lyophilised powder. For in vitro or preclinical in vivo studies, you’ll typically reconstitute it using sterile bacteriostatic water. Once it’s reconstituted, the peptide stays relatively stable if kept at 4°C and used promptly, though it’s better to store the lyophilised form at −20°C or colder for the long haul. Try to avoid repeated freeze-thaw cycles, as they can degrade the peptide’s integrity over time. Standard practice for characterising GHS peptides involves confirming purity and molecular weight through HPLC and mass spectrometry before starting any experimental work.

This product is intended for research purposes only. It is not approved for human therapeutic use and is not intended for consumption or clinical application.

References

• • Bowers CY, et al. Structure-activity relationships of a synthetic hexapeptide that specifically releases GH in vitro and in vivo in animals. 1994;134(4):1517–1524.
  • Muccioli G, et al. Hexarelin, a synthetic GH-releasing peptide, exerts cardioprotective activity in models of ischemia-reperfusion injury. Eur J Pharmacol. 2004;491(2–3):209–217.
  • Torsello A, et al. Growth hormone secretagogues and the cardiovascular system. J Endocrinol Invest. 1999;22(5 Suppl):27–33.
  • Gnanapavan S, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87(6):2988.